Familial hemophagocytic lymphohistiocytosis: When rare diseases shed light on immune system functioning

Frontiers in Immunology

Volumn 5, Issue APR, 2014, Pages

  Sieni, Elena ^a   Cetica, Valentina ^a,b   Hackmann, Yvonne ^c   Coniglio, Maria Luisa ^a   Da Ros, Martina ^a   Ciambotti, Benedetta ^a   Pende, Daniela ^d   Griffiths, Gillian ^c   Aricò, Maurizio ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

Cellular cytotoxicity; Hemophagocytosis; Mutation analysis; Natural killer

Indexed keywords

ALEMTUZUMAB; CALRETICULIN; DEXAMETHASONE; ETOPOSIDE; FAS LIGAND; FERRITIN; FIBRINOGEN; FLUDARABINE; GAMMA INTERFERON; GAMMA INTERFERON ANTIBODY; GRANULYSIN; GRANZYME; INTERLEUKIN 2 RECEPTOR ALPHA; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MELPHALAN; NI 05 01; PERFORIN; RAB27A PROTEIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SYNTAXIN; SYNTAXIN 11; THYMOCYTE ANTIBODY; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ARTHRITIS; ARTICLE; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; CHEDIAK HIGASHI SYNDROME; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ERYTHROPHAGOCYTOSIS; FLOW CYTOMETRY; GENE MUTATION; GENE SEQUENCE; GRISCELLI SYNDROME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC SYNDROME; HUMAN; IMMUNE DEFICIENCY; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MACROPHAGE ACTIVATION SYNDROME; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NATURAL KILLER T CELL; OCULAR ALBINISM; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROTEIN EXPRESSION; RHEUMATIC DISEASE; X INKED LYMPHOPROLIFERATIVE SYNDROME TYPE 2; X LINKED LYMPHOPROLIFERATIVE DISEASE 1;

EID: 84900860054     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00167     Document Type: Article

References (186)

1. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science (2011) 331(6013):44-9. doi:10.1126/science.1198687.
2. Montaldo E, Del Zotto G, Della Chiesa M, Mingari MC, Moretta A, De Maria A, et al. Human NK cell receptors/markers: a tool to analyze NK cell development, subsets and function. Cytometry A (2013) 83(8):702-13. doi:10.1002/cyto.a.22302.
3. Stinchcombe JC, Majorovits E, Bossi G, Fuller S, Griffiths GM. Centrosome polarization delivers secretory granules to the immunological synapse. Nature (2006) 443(7110):462-5. doi:10.1038/nature05071.
4. Kerdiles Y, Ugolini S, Vivier E. T cell regulation of natural killer cells. J Exp Med (2013) 210(6):1065-8. doi:10.1084/jem.20130960.
5. Sieni E, Cetica V, Mastrodicasa E, Pende D, Moretta L, Griffiths G, et al. Familial hemophagocytic lymphohistiocytosis: a model for understanding the human machinery of cellular cytotoxicity. Cell Mol Life Sci (2012) 69(1):29-40. doi:10.1007/s00018-011-0835-y.
6. Kotevski A, Cook WD, Vaux DL, Callus BA. Identification of an Xiap-like pseudogene on mouse chromosome 7. PLoS One (2009) 4:e8078. doi:10.1371/journal.pone.0008078.
7. Cetica V, Pende D, Griffiths GM, Aricò M. Molecular basis of familial hemophagocytic lymphohistiocytosis. Haematologica (2010) 95:538-41. doi:10.3324/haematol.2009.019562.
8. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain S, Mathew PA, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science (1999) 286(5446):1957-9. doi:10.1126/science.286.5446.1957.
9. Zur Stadt U, Beutel K, Kolberg S, Schneppenheim R, Kabisch H, Janka G, et al. Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A. Hum Mutat (2006) 27(1):62-8. doi:10.1002/humu.20274.
10. Trizzino A, zur Stadt U, Ueda I, Risma K, Janka G, Ishii E, et al. Genoptype-phenotype study of familial haemophagocytic lymphohistiocytosis due to perforin mutations. J Med Genet (2008) 45:15-21. doi:10.1136/jmg.2007.052670.
11. Clementi R, zur Stadt U, Savoldi G, Varoitto S, Conter V, De Fusco C, et al. Six novel mutations in the PRF1 gene in children with haemophagocytic lymphohistiocytosis. J Med Genet (2001) 38:643-6. doi:10.1136/jmg.38.9.643.
12. Göransdotter Ericson K, Fadeel B, Nilsson-Ardnor S, Söderhäll C, Samuelsson A, Janka G, et al. Spectrum of perforin gene muations in familial hemophagocytic lymphohistiocytosis. Am J Hum Genet (2001) 68:590-7. doi:10.1086/318796.
13. Feldmann J, Le Deist F, Ouachée-Chardin M, Certain S, Alexander S, Quartier P, et al. Functional consequences of perforin gene mutations in 22 patients with familial haemophagocytic lymphohistiocytosis. Br J Haematol (2002) 117(4):965-72. doi:10.1046/j.1365-2141.2002.03534.x.
14. Kogawa K, Lee SM, Villanueva J, Marmer D, Sumegi J, Filipovich AH. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood (2002) 99(1):61-6. doi:10.1182/blood.V99.1.61.
15. Suga N, Takada H, Nomura A, Ohga S, Ishii E, Ihara K, et al. Perforin defects of primary haemophagocytic lymphohistiocytosis in Japan. Br J Haematol (2002) 116:346-9. doi:10.1046/j.1365-2141.2002.03266.x.
16. Ueda I, Morimoto A, Inaba T, Yagi T, Hibi S, Sugimoto T, et al. Characteristic peforin gene mutations of haemophagocytic lymphohistiocytosis in Japan. Br J Haematol (2003) 121:503-10. doi:10.1046/j.1365-2141.2003.04298.x.
17. Molleran Lee S, Villanueva J, Sumegi J, Zhang K, Kogawa K, Davis J, et al. Characterisation of diverse PRF1 mutations leading to decreased killer cell activity in North American families with haemophagocytic lymphohistiocytosis. J Med Genet (2004) 41:137-44. doi:10.1136/jmg.2003.011528.
18. An O, Gursoy A, Gurgey A, Keskin O. Structural and functional analysis of perforin mutations in association with clinical data of familial hemophagocytic lymphohistiocytosis type 2 (FHL2) patients. Protein Sci (2013) 22(6):823-39. doi:10.1002/pro.2265.
19. Lee SM, Sumegi J, Villanueva J, Tabata Y, Zhang K, Chakraborty R, et al. Patients of African ancestry with hemophagocytic lymphohistiocytosis share a common haplotype of PRF1 with a 50delT mutation. J Pediatr (2006) 149(1):134-7. doi:10.1016/j.jpeds.2006.03.003.
20. Santoro A, Cannella S, Trizzino A, Lo Nigro L, Corsello G, Aricò M. A single amino acid change A91V in perforin: a novel, frequent predisposing factor to childhood acute lymphoblastic leukemia? Haematologica (2005) 90(5):697-8.
21. Trapani JA, Thia KY, Andrews M, Davis ID, Gedye C, Parente P, et al. Human perforin mutations and susceptibility to multiple primary cancers. Oncoimmunology (2013) 2(4):e24185. doi:10.4161/onci.24185.
22. Trambas C, Gallo F, Pende D, Marcenaro S, Moretta L, De Fusco C, et al. A single amino acid change, A91V, leads to conformational changes that can impair processing to the active form of perforin. Blood (2005) 106(3):932-7. doi:10.1182/blood-2004-09-3713.
23. Martínez-Pomar N, Lanio N, Romo N, Lopez-Botet M, Matamoros N. Functional impact of A91V mutation of the PRF1 perforin gene. Hum Immunol (2013) 74(1):14-7. doi:10.1016/j.humimm.2012.10.011.
24. Zhang K, Jordan MB, Marsh RA, Johnson JA, Kissell D, Meller J, et al. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood (2011) 118(22):5794-8. doi:10.1182/blood-2011-07-370148.
25. Feldmann J, Callebaut I, Raposo G, Certain S, Bacq D, Dumont C, et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell (2003) 115(4):461-73. doi:10.1016/S0092-8674(03)00855-9.
26. Rudd E, Bryceson YT, Zheng C, Edner J, Wood SM, Ramme K, et al. Spectrum, and clinical and functional implications of UNC13D mutations in familial haemophagocytic lymphohistiocytosis. J Med Genet (2008) 45(3):134-41. doi:10.1136/jmg.2007.054288.
27. Santoro A, Cannella S, Bossi G, Gallo F, Trizzino A, Pende D, et al. Novel Munc13-4 mutations in children and young adult patients with haemophagocytic lymphohistiocytosis. J Med Genet (2006) 43(12):953-60. doi:10.1136/jmg.2006.041863.
28. Sieni E, Cetica V, Santoro A, Beutel K, Mastrodicasa E, Meeths M, et al. Genoptype-phenotype study of familial haemophagocytic lymphohistiocytosis type 3. J Med Genet (2011) 48(5):343-52. doi:10.1136/jmg.2010.085456.
29. Santoro A, Cannella S, Trizzino A, Bruno G, De Fusco C, Notarangelo LD, et al. Mutations affecting mRNA splicing are the most common molecular defect in patients with familial hemophagocytic lymphohistiocytosis type 3. Haematologica (2008) 93(7):1086-90. doi:10.3324/haematol.12622.
30. Meeths M, Chiang SC, Wood SM, Entesarian M, Schlums H, Bang B, et al. Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) caused by deep intronic mutation and inversion in UNC13D. Blood (2011) 118(22):5783-93. doi:10.1182/blood-2011-07-369090.
31. Entesarian M, Chiang SC, Schlums H, Meeths M, Chan MY, Mya SN, et al. Novel deep intronic and missense UNC13D mutations in familial haemophagocytic lymphohistiocytosis type 3. Br J Haematol (2013) 162(3):415-8. doi:10.1111/bjh.12371.
32. Yoon HS, Kim HJ, Yoo KH, Sung KW, Koo HH, Kang HJ, et al. UNC13D is the predominant causative gene with recurrent splicing mutations in Korean patients with familial hemophagocytic lymphohistiocytosis. Haematologica (2010) 95:622-6. doi:10.3324/haematol.2009.016949.
33. zur Stadt U, Schmidt S, Kasper B, Beutel K, Diler AS, Henter JI, et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type 4 to chromosome 6q24 and identification of mutation in syntaxin 11. Hum Mol Genet (2005) 14:827-34. doi:10.1093/hmg/ddi076.
34. Bryceson YT, Rudd E, Zheng C, Edner J, Ma D, Wood SM, et al. Defective cytotoxic lymphocyte egranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. Blood (2007) 110:1906-15. doi:10.1182/blood-2007-02-074468.
35. Rudd E, Göransdotter Ericson K, Zheng C, Uysal Z, Ozkan A, Gürgey A, et al. Spectrum and clinical implications of syntaxin 11 gene mutations in familial haemophagocytic lymphohistiocytosis: association with disease-free remissions and haematopoietic malignancies. J Med Genet (2006) 43(4):e14. doi:10.1136/jmg.2005.035253.
36. Marsh RA, Satake N, Biroschak J, Jacobs T, Johnson J, Jordan MB, et al. STX11 mutations and clinical phenotypes of familial hemophagocytic lymphohistiocytosis in North America. Pediatr Blood Cancer (2010) 55(1):134-40. doi:10.1002/pbc.22499.
37. Horne A, Ramme KG, Rudd E, Zheng C, Wali Y, al-Lamki Z, et al. Characterization of PRF1, STX11 and UNC13D genotype-phenotype correlations in familial hemophagocytic lymphohistiocytosis. Br J Haematol (2008) 143(1):75-83. doi:10.1111/j.1365-2141.2008.07315.x.
38. Sepulveda FE, Debeurme F, Ménasché G, Kurowska M, Côte M, Pachlopnik Schmid J, et al. Distinct severity of HLH in both human and murine mutants with complete loss of cytotoxic effector PRF1, RAB27A, and STX11. Blood (2013) 121:595-603. doi:10.1182/blood-2012-07-440339.
39. Müller ML, Chiang SC, Meeths M, Tesi B, Entesarian M, Nilsson D, et al. An N-terminal missense mutation in STX11 causative of FHL4 abrogates syntaxin-11 binding to Munc18-2. Front Immunol (2014) 4:515. doi:10.3389/fimmu.2013.00515.
40. Côte M, Ménager MM, Burgess A, Mahlaoui N, Picard C, Schaffner C, et al. Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells. J Clin Invest (2009) 119(12):3765-73. doi:10.1172/JCI40732.
41. zur Stadt U, Rohr J, Seifert W, Koch F, Grieve S, Pagel J, et al. Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11. Am J Hum Genet (2009) 85(4):482-92. doi:10.1016/j.ajhg.2009.09.005.
42. Pagel J, Beutel K, Lehmberg K. Distinct mutations in STXBP2 are associated with variable clinical presentations in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5). Blood (2012) 119(25):6016-24. doi:10.1182/blood-2011-12-398958.
43. Nagai K, Yamamoto K, Fujiwara H, An J, Ochi T, Suemori K, et al. Subtypes of familial hemophagocytic lymphohistiocytosis in Japan based on genetic and functional analyses of cytotoxic T lymphocytes. PLoS One (2010) 5(11):e14173. doi:10.1371/journal.pone.0014173.
44. Cetica V, Santoro A, Gilmour KC, Sieni E, Beutel K, Pende D, et al. STXBP2 mutations in children with familial haemophagocytic lymphohistiocytosis type 5. J Med Genet (2010) 47:595-600. doi:10.1136/jmg.2009.075341.
45. Stepensky P, Bartram J, Barth TF, Lehmberg K, Walther P, Amann K, et al. Persistent defective membrane trafficking in epithelial cells of patients with familial hemophagocytic lymphohistiocytosis type 5 due to STXBP2/MUNC18-2 mutations. Pediatr Blood Cancer (2013) 60(7):1215-22. doi:10.1002/pbc.24475.
46. Zhao XW, Gazendam RP, Drewniak A, van Houdt M, Tool AT, van Hamme JL, et al. Defects in neutrophil granule mobilization and bactericidal activity in familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) syndrome caused by STXBP2/Munc18-2 mutations. Blood (2013) 122:109-11. doi:10.1182/blood-2013-03-494039.
47. Sandrock K, Nakamura L, Vraetz T, Beutel K, Ehl S, Zieger B. Platelet secretion defect in patients with familial hemophagocytic lymphohistiocytosis type 5 (FHL-5). Blood (2010) 116:6148-50. doi:10.1182/blood-2010-08-302943.
48. Meeths M, Entesarian M, Al-Herz W, Chiang SC, Wood SM, Al-Ateeqi W, et al. Spectrum of clinical presentations in familial hemophagocytic lymphohistiocytosis type 5 patients with mutations in STXBP2. Blood (2010) 116:2635-43. doi:10.1182/blood-2010-05-282541.
49. Al Hawas R, Ren Q, Ye S, Karim ZA, Filipovich AH, Whiteheart SW. Munc18b/STXBP2 is required for platelet secretion. Blood (2012) 120:2493-500. doi:10.1182/blood-2012-05-430629.
50. Coffey AJ, Brooksbank RA, Brandau O, Oohashi T, Howell GR, Bye JM, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet (1998) 20:129-35. doi:10.1038/2424.
51. Filipovich AH, Zhang K, Snow AL, Marsh RA. X-linked lymphoproliferative syndromes: brothers or distant cousins? Blood (2010) 116(18):3398-408. doi:10.1182/blood-2010-03-275909.
52. Palendira U, Low C, Chan A, Hislop AD, Ho E, Phan TG, et al. Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP. PLoS Biol (2011) 9(11):e1001187. doi:10.1371/journal.pbio.1001187.
53. Parolini S, Bottino C, Falco M, Augugliaro R, Giliani S, Franceschini R, et al. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J Exp Med (2000) 192:337-46. doi:10.1084/jem.192.3.337.
54. + T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets. Blood (2010) 116(17):3249-57. doi:10.1182/blood-2009-09-238832.
55. + T cells against EBV-infected cells. Blood (2005) 105(11):4383-9. doi:10.1182/blood-2004-08-3269.
56. Rezaei N, Mahmoudi E, Aghamohammadi A, Das R, Nichols KE. X-linked lymphoproliferative syndrome: a genetic condition typified by the triad of infection, immunodeficiency and lymphoma. Br J Haematol (2011) 152(1):13-30. doi:10.1111/j.1365-2141.2010.08442.x.
57. Meazza R, Tuberosa C, Cetica V, Falco M, Loiacono F, Parolini S, et al. XLP1 inhibitory effect by 2B4 does not affect DNAM-1 and NKG2D activating pathways in NK cells. Eur J Immunol (2014). doi:10.1002/eji.201344312.
58. Nichols KE, Ma CS, Cannons JL, Schwartzberg PL, Tangye SG. Molecular and cellular pathogenesis of X-linked lymphoproliferative disease. Immunol Rev (2005) 203:180-99. doi:10.1111/j.0105-2896.2005.00230.x.
59. Booth C, Gilmour KC, Veys P, Gennery AR, Slatter MA, Chapel H, et al. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood (2011) 117:53-62. doi:10.1182/blood-2010-06-284935.
60. Arico M, Imashuku S, Clementi R, Hibi S, Teramura T, Danesino C, et al. Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene. Blood (2001) 97(4):1131-3. doi:10.1182/blood.V97.4.1131.
61. Recher M, Fried AJ, Massaad MJ, Kim HY, Rizzini M, Frugoni F, et al. Intronic SH2D1A mutation with impaired SAP expression and agammaglobulinemia. Clin Immunol (2013) 146(2):84-9. doi:10.1016/j.clim.2012.11.007.
62. Rigaud S, Fondanèche MC, Lambert N, Pasquier B, Mateo V, Soulas P, et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature (2006) 444:110-4. doi:10.1038/nature05257.
63. Damgaard RB, Fiil BK, Speckmann C, Yabal M, zur Stadt U, Bekker-Jensen S, et al. Disease-causing mutations in the XIAP BIR2 domain impair NOD2-dependent immune signalling. EMBO Mol Med (2013) 5(8):1278-95. doi:10.1002/emmm.201303090.
64. Pachlopnik Schmid J, Canioni D, Moshous D, Touzot F, Mahlaoui N, Hauck F, et al. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood (2011) 117:1522-9. doi:10.1182/blood-2010-07-298372.
65. Marsh RA, Madden L, Kitchen BJ, Mody R, McClimon B, Jordan MB, et al. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood (2010) 116:1079-82. doi:10.1182/blood-2010-01-256099.
66. Speckmann C, Lehmberg K, Albert MH, Damgaard RB, Fritsch M, Gyrd-Hansen M, et al. X-linked inhibitor of apoptosis (XIAP) deficiency: the spectrum of presenting manifestations beyond hemophagocytic lymphohistiocytosis. Clin Immunol (2013) 149(1):133-41. doi:10.1016/j.clim.2013.07.004.
67. Marsh RA, Villanueva J, Kim MO, Zhang K, Marmer D, Risma KA, et al. Patients with X-linked lymphoproliferative disease due to BIRC4 mutation have normal invariant natural killer T-cell populations. Clin Immunol (2009) 132(1):116-23. doi:10.1016/j.clim.2009.03.517.
68. Marsh RA, Kim MO, Liu C, Bellman D, Hart L, Grimley M, et al. An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Biol Blood Marrow Transplant (2013) 19:1625-31. doi:10.1016/j.bbmt.2013.09.001.
69. Barbosa MD, Barrat FJ, Tchernev VT, Nguyen QA, Mishra VS, Colman SD, et al. Identification of the homologous beige and Chediak-Higashi syndrome genes. Nature (1996) 382:262-5. doi:10.1038/382262a0.
70. Chediak MM. New leukocyte anomaly of constitutional and familial character. Rev Hematol (1952) 7:362-7.
71. Higashi O. Congenital gigantism of peroxidase granules; the first case ever reported of qualitative abnormality of peroxidase. Tohoku J Exp Med (1954) 59:315-32. doi:10.1620/tjem.59.315.
72. Introne W, Boissy RE, Gahl WA. Clinical, molecular, and cell biological aspects of Chediak-Higashi syndrome. Mol Genet Metab (1999) 68:283-303. doi:10.1006/mgme.1999.2927.
73. Karim MA, Suzuki K, Fukai K, Oh J, Nagle DL, Moore KJ, et al. Apparent genotype-phenotype correlation in childhood, adolescent, and adult Chediak-Higashi syndrome. Am J Med Genet (2002) 108(1):16-22. doi:10.1002/ajmg.10184.abs.
74. Shimazaki H, Honda J, Naoi T, Namekawa M, Nakano I, Yazaki M, et al. Autosomal-recessive complicated spastic paraplegia with a novel lysosomal trafficking regulator gene mutation. J Neurol Neurosurg Psychiatry (2014). doi:10.1136/jnnp-2013-306981.
75. Griscelli C, Durandy A, Guy-Grand D, Daguillard F, Herzog C, Prunieras M. A syndrome associating partial albinism and immunodeficiency. Am J Med (1978) 65:691-702. doi:10.1016/0002-9343(78)90858-6.
76. Jancic C, Savina A, Wasmeier C, Tolmachova T, El-Benna J, Dang PM, et al. Rab27a regulates phagosomal pH and NADPH oxidase recruitment to dendritic cell phagosomes. Nat Cell Biol (2007) 9(4):367-78. doi:10.1038/ncb1552.
77. Meeths M, Bryceson YT, Rudd E, Zheng C, Wood SM, Ramme K, et al. Clinical presentation of Griscelli syndrome type 2 and spectrum of RAB27A mutations. Pediatr Blood Cancer (2010) 54(4):563-72. doi:10.1002/pbc.22357.
78. Hermansky F, Pudlak P. Albinism associated with hemorrhagic diathesis and unusual pigmented reticular cells in the bone marrow: report of two cases with histochemical studies. Blood (1959) 14:162-9.
79. Dotta L, Parolini S, Prandini A, Tabellini G, Antolini M, Kingsmore SF, et al. Clinical, laboratory and molecular signs of immunodeficiency in patients with partial oculo-cutaneous albinism. Orphanet J Rare Dis (2013) 8:168. doi:10.1186/1750-1172-8-168.
80. Dell'Angelica EC, Shotelersuk V, Aguilar RC, Gahl WA, Bonifacino JS. Altered trafficking of lysosomal proteins in Hermansky-Pudlak syndrome due to mutations in the beta 3A subunit of the AP-3 adaptor. Mol Cell (1999) 3:11-21. doi:10.1016/S1097-2765(00)80170-7.
81. Jones ML, Murden SL, Brooks C, Maloney V, Manning RA, Gilmour KC, et al. Disruption of AP3B1 by a chromosome 5 inversion: a new disease mechanism in Hermansky-Pudlak syndrome type 2. BMC Med Genet (2013) 14:42. doi:10.1186/1471-2350-14-42.
82. Enders A, Zieger B, Schwarz K, Yoshimi A, Speckmann C, Knoepfle EM, et al. Lethal hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type II. Blood (2006) 108:81-7. doi:10.1182/blood-2005-11-4413.
83. Jessen B, Bode SF, Ammann S, Chakravorty S, Davies G, Diestelhorst J, et al. The risk of hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type 2. Blood (2013) 121(15):2943-51. doi:10.1182/blood-2012-10-463166.
84. Arico M, Janka G, Fischer A, Henter JI, Blanche S, Elinder G, et al. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. Leukemia (1996) 10:197-203.
85. Rego I, Severino M, Micalizzi C, Faraci M, Pende D, Dufour C, et al. Neuroradiologic findings and follow-up with magnetic resonance imaging of the genetic forms of haemophagocytic lymphohistiocytosis with CNS involvement. Pediatr Blood Cancer (2012) 58(5):810-4. doi:10.1002/pbc.23405.
86. Xu XJ, Tang YM, Song H, Yang SL, Xu WQ, Zhao N, et al. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J Pediatr (2012) 160(6):984-90.e1. doi:10.1016/j.jpeds.2011.11.046.
87. Ryu JM, Kim KM, Oh SH, Koh KN, Im HJ, Park CJ, et al. Differential clinical characteristics of acute liver 15 failure caused by hemophagocytic lymphohistiocytosis in children. Pediatr Int (2013) 55:748-52. doi:10.1111/ped.12181.
88. Henter JI, Horne A, Aricò M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer (2007) 48:124-31. doi:10.1002/pbc.21039.
89. Allen M, De Fusco C, Legrand F, Clementi R, Conter V, Danesino C, et al. Familial hemophagocytic lymphohistiocytosis: how late can the onset be? Haematologica (2001) 86:499-503.
90. Manno EC, Salfa I, Palma P, Bertaina A, Lombardi A, Moretta F, et al. Familial hemophagocytic lymphohistiocytosis type 3 diagnosed at school age: a case report. J Pediatr Hematol Oncol (2014) 36(2):e128-30. doi:10.1097/MPH.0b013e318292bc7c.
91. Clementi R, Emmi L, Maccario R, Liotta F, Moretta L, Danesino C, et al. Adult onset and atypical presentation of hemophagocytic lymphohistiocytosis in siblings carrying PRF1 mutations. Blood (2002) 100(6):2266-7. doi:10.1182/blood-2002-04-1030.
92. Sieni E, Cetica V, Piccin A, Gherlinzoni F, Sasso FC, Rabusin M, et al. Familial hemophagocytic lymphohistiocytosis may present during adulthood: clinical and genetic features of a small series. PLoS One (2012) 7(9):e44649. doi:10.1371/journal.pone.0044649.
93. Gagnaire MH, Galambrun C, Stéphan JL. Hemophagocytic syndrome: a misleading complication of visceral leishmaniasis in children-a series of 12 cases. Pediatrics (2000) 106:E58. doi:10.1542/peds.106.4.e58.
94. Bryceson YT, Pende D, Maul-Pavicic A, Gilmour KC, Ufheil H, Vraetz T, et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood (2012) 119(12):2754-63. doi:10.1182/blood-2011-08-374199.
95. Marcenaro S, Gallo F, Martini S, Santoro A, Griffiths GM, Aricó M, et al. Analysis of natural killer-cell function in familial hemophagocytic lymphohistiocytosis (FHL): defective CD107a surface expression heralds Munc13-4 defect and discriminates between genetic subtypes of the disease. Blood (2006) 108:2316-23. doi:10.1182/blood-2006-04-015693.
96. Trottestam H, Horne A, Aricò M, Egeler RM, Filipovich AH, Gadner H, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood (2011) 118(17):4577-84. doi:10.1182/blood-2011-06-356261.
97. Cooper N, Rao K, Gilmour K, Hadad L, Adams S, Cale C, et al. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood (2006) 107:1233-6. doi:10.1182/blood-2005-05-1819.
98. Marsh RA, Vaughn G, Kim MO, Li D, Jodele S, Joshi S, et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood (2010) 116:5824-31. doi:10.1182/blood-2010-04-282392.
99. Marsh RA, Rao K, Satwani P, Lehmberg K, Müller I, Li D, et al. Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes. Blood (2013) 121:877-83. doi:10.1182/blood-2012-06-432500.
100. Terrell CE, Jordan MB. Mixed hematopoietic or T-cell chimerism above a minimal threshold restores perforin-dependent immune regulation in perforin-deficient mice. Blood (2013) 122:2618-21. doi:10.1182/blood-2013-06-508143.
101. Caselli D, Farruggia P, Trizzino A, Cannella S, Santoro A, Locatelli F, et al. Split chimerism may be enough to cure Evans syndrome. Bone Marrow Transplant (2006) 38:311. doi:10.1038/sj.bmt.1705427.
102. Stéphan JL, Donadieu J, Ledeist F, Blanche S, Griscelli C, Fischer A. Treatment of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins, steroids, and cyclosporin A. Blood (1993) 82:2319-23.
103. Mahlaoui N, Ouachée-Chardin M, de Saint Basile G, Neven B, Picard C, Blanche S, et al. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients. Pediatrics (2007) 120(3):e622-8. doi:10.1542/peds.2006-3164.
104. Rivat C, Booth C, Alonso-Ferrero M, Blundell M, Sebire NJ, Thrasher AJ, et al. SAP gene transfer restores cellular and humoral immune function in a murine model of X-linked lymphoproliferative disease. Blood (2013) 121(7):1073-6. doi:10.1182/blood-2012-07-445858.
105. Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr (2005) 146(5):598-604. doi:10.1016/j.jpeds.2004.12.016.
106. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child (2001) 85:421-6. doi:10.1136/adc.85.5.421.
107. Grom AA, Mellins ED. Macrophage activation syndrome: advances towards understanding pathogenesis. Curr Opin Rheumatol (2010) 22(5):561-6. doi:10.1097/01.bor.0000381996.69261.71.
108. Ravelli A, Grom AA, Behrens EM, Cron RQ. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun (2012) 13(4):289-98. doi:10.1038/gene.2012.3.
109. Wulffraat NM, Rijkers GT, Elst E, Brooimans R, Kuis W. Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology (Oxford) (2003) 42(2):375-9. doi:10.1093/rheumatology/keg074.
110. Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A, et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther (2005) 7:R30-7. doi:10.1186/ar1551.
111. Unal S, Balta G, Okur H, Aytac S, Cetin M, Gumruk F, et al. Recurrent macrophage activation syndrome associated with heterozygous perforin W374X gene mutation in a child with systemic juvenile idiopathic arthritis. J Pediatr Hematol Oncol (2013) 35(5):e205-8. doi:10.1097/MPH.0b013e31827b4859.
112. Ueda I, Kurokawa Y, Koike K, Ito S, Sakata A, Matsumora T, et al. Late-onset cases of familial hemophagocytic lymphohistiocytosis with missense perforin gene mutations. Am J Hematol (2007) 82(6):427-32. doi:10.1002/ajh.20878.
113. Sánchez IP, Leal-Esteban LC, Álvarez-Álvarez JA, Pérez-Romero CA, Orrego JC, Serna ML, et al. Analyses of the PRF1 gene in individuals with hemophagocytic lymphohystiocytosis reveal the common haplotype R54C/A91V in Colombian unrelated families associated with late onset disease. J Clin Immunol (2012) 32(4):670-80. doi:10.1007/s10875-012-9680-5.
114. Mancebo E, Allende LM, Guzmán M, Paz-Artal E, Gil J, Urrea-Moreno R, et al. Familial hemophagocytic lymphohistiocytosis in an adult patient homozygous for A91V in the perforin gene, with tuberculosis infection. Haematologica (2006) 91(9):1257-60.
115. Nagafuji K, Nonami A, Kumano T, Kikushige Y, Yoshimoto G, Takenaka K, et al. Perforin gene mutations in adult-onset hemophagocytic lymphohistiocytosis. Haematologica (2007) 92(7):978-81. doi:10.3324/haematol.11233.
116. Sumegi J, Nestheide SV, Barnes MG, Villanueva J, Zhang K, Grom AA, et al. Gene-expression signatures differ between different clinical forms of familial hemophagocytic lymphohistiocytosis. Blood (2013) 121:e14-24. doi:10.1182/blood-2012-05-425769.
117. Schuetz JM, Daley D, Graham J, Berry BR, Gallagher RP, Connors JM, et al. Genetic variation in cell death genes and risk of non-Hodgkin lymphoma. PLoS One (2012) 7(2):e31560. doi:10.1371/journal.pone.0031560.
118. Falini B, Pileri S, De Solas I, Martelli MF, Mason DY, Delsol G, et al. Peripheral T-cell lymphoma associated with hemophagocytic syndrome. Blood (1990) 75(2):434-44.
119. Aricò M. Peripheral T-cell lymphoma associated with hemophagocytic syndrome and hemophagocytic lymphohistiocytosis of children: do they share something? Blood (1990) 76(10):2163-4.
120. El Abed R, Bourdon V, Voskoboinik I, Omri H, Youssef YB, Laatiri MA, et al. Molecular study of the perforin genein familial hematological malignancies. Hered Cancer Clin Pract (2011) 9(1):9. doi:10.1186/1897-4287-9-9.
121. Muralitharan S, Wali Y, Pathare AV. Perforin A91V polymorphism and putative susceptibility to hematological malignancies. Leukemia (2006) 20(12):2178. doi:10.1038/sj.leu.2404433.
122. Clementi R, Dagna L, Dianzani U, Dupré L, Dianzani I, Ponzoni M, et al. Inherited perforin and Fas mutations in a patient with autoimmune lymphoproliferative syndrome and lymphoma. N Engl J Med (2004) 351(14):1419-24. doi:10.1056/NEJMoa041432.
123. Clementi R, Locatelli F, Dupré L, Garaventa A, Emmi L, Bregni M, et al. A proportion of patients with lymphoma may harbor mutations of the perforin gene. Blood (2005) 105(11):4424-8. doi:10.1182/blood-2004-04-1477.
124. Cannella S, Santoro A, Bruno G, Pillon M, Mussolin L, Mangili G, et al. Germline mutations of the perforin gene are a frequent occurrence in childhood anaplastic large cell lymphoma. Cancer (2007) 109(12):2566-71. doi:10.1002/cncr.22718.
125. Ciambotti B, Mussolin L, d'Amore ES, Pillon M, Sieni E, Coniglio ML, et al. Monoallelic mutations of the perforin gene may represent a predisposing factor to childhood anaplastic large cell lymphoma. J Pediatr Hematol Oncol (2013). doi:10.1097/MPH.0000000000000073.
126. Sandlund JT, Shurtleff SA, Onciu M, Horwitz E, Leung W, Howard V, et al. Frequent mutations in SH2D1A (XLP) in males presenting with high-grade mature B-cell neoplasms. Pediatr Blood Cancer (2013) 60:E85-7. doi:10.1002/pbc.24525.
127. Mehta PA, Davies SM, Kumar A, Devidas M, Lee S, Zamzow T, et al. Perforin polymorphism A91V and susceptibility to B-precursor childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia (2006) 20(9):1539-41. doi:10.1038/sj.leu.2404299.
128. Chia J, Yeo KP, Whisstock JC, Dunstone MA, Trapani JA, Voskoboinik I. Temperature sensitivity of human perforin mutants unmasks subtotal loss of cytotoxicity, delayed FHL, and a predisposition to cancer. Proc Natl Acad Sci U S A (2009) 106(24):9809-14. doi:10.1073/pnas.0903815106.
129. Bolitho P, Street SE, Westwood JA, Edelmann W, Macgregor D, Waring P, et al. Perforin-mediated suppression of B-cell lymphoma. Proc Natl Acad Sci U S A (2009) 106(8):2723-8. doi:10.1073/pnas.0809008106.
130. Clementi R, Chiocchetti A, Cappellano G, Cerutti E, Ferretti M, Orilieri E, et al. Variations of the perforin gene in patients with autoimmunity/lymphoproliferation and defective Fas function. Blood (2006) 108:3079-84. doi:10.1182/blood-2006-02-001412.
131. Aricò M, Boggio E, Cetica V, Melensi M, Orilieri E, Clemente N, et al. Variations of the UNC13D gene in patients with autoimmune lymphoproliferative syndrome. PLoS One (2013) 8(7):e68045. doi:10.1371/journal.pone.0068045.
132. Komori H, Furukawa H, Mori S, Ito MR, Terada M, Zhang MC, et al. A signal adaptor SLAM-associated protein regulates spontaneous autoimmunity and Fas-dependent lymphoproliferation in MRL-Fas lpr lupus mice. J Immunol (2006) 176:395-400.
133. Boggio E, Melensi M, Bocca S, Chiocchetti A, Comi C, Clemente N, et al. The -346T polymorphism of the SH2D1A gene is a risk factor for development of autoimmunity/lymphoproliferation in males with defective Fas function. Hum Immunol (2012) 73(5):585-92. doi:10.1016/j.humimm.2012.02.025.
134. Cappellano G, Orilieri E, Comi C, Chiocchetti A, Bocca S, Boggio E, et al. Variations of the perforin gene in patients with multiple sclerosis. Genes Immun (2008) 9:438-44. doi:10.1038/gene.2008.35.
135. Hazen MM, Woodward AL, Hofmann I, Degar BA, Grom A, Filipovich AH, et al. Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis. Arthritis Rheum (2008) 58:567-70. doi:10.1002/art.23199.
136. Zhang K, Biroschak J, Glass DN, Thompson SD, Finkel T, Passo MH, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum (2008) 58(9):2892-6. doi:10.1002/art.23734.
137. Vastert SJ, van Wijk R, D'Urbano LE, de Vooght KM, de Jager W, Ravelli A, et al. Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) (2010) 49(3):441-9. doi:10.1093/rheumatology/kep418.
138. Moshous D, Feyen O, Lankisch P, Schwarz K, Schaper J, Schneider M, et al. Primary necrotizing lymphocytic central nervous system vasculitis due to perforin deficiency in a four-year-old girl. Arthritis Rheum (2007) 56(3):995-9. doi:10.1002/art.22442.
139. Chen RL, Hsu YH, Ueda I, Imashuku S, Takeuchi K, Tu BP, et al. Cytophagic histiocytic panniculitis with fatal haemophagocytic lymphohistiocytosis in a paediatric patient with perforin gene mutation. J Clin Pathol (2007) 60(10):1168-9. doi:10.1136/jcp.2007.049551.
140. Pasqualini C, Jorini M, Carloni I, Giangiacomi M, Cetica V, Aricò M, et al. Cytophagic histiocytic panniculitis, hemophagocytic lymphohistiocytosis and undetermined autoimmune disorder: reconciling the puzzle. Ital J Pediatr (2014) 40(1):17. doi:10.1186/1824-7288-40-17.
141. Orilieri E, Cappellano G, Clementi R, Cometa A, Ferretti M, Cerutti E, et al. Variations of the perforin gene in patients with type 1 diabetes. Diabetes (2008) 57(4):1078-83. doi:10.2337/db07-0947.
142. Weiss KH, Runz H, Noe B, Gotthardt DN, Merle U, Ferenci P, et al. Genetic analysis of BIRC4/XIAP as a putative modifier gene of Wilson disease. J Inherit Metab Dis (2010) 33(Suppl 3):S233-40. doi:10.1007/s10545-010-9123-5.
143. Ferretti M, Gattorno M, Chiocchetti A, Mesturini R, Orilieri E, Bensi T, et al. The 423Q polymorphism of the X-linked inhibitor of apoptosis gene influences monocyte function and is associated with periodic fever. Arthritis Rheum (2009) 60(11):3476-84. doi:10.1002/art.24905.
144. Ou DY, Luo JM, Yuan Y. XIAP Q423P polymorphism and susceptibility to childhood hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer (2014) 61(2):196-7. doi:10.1002/pbc.24735.
145. Eissmann P, Beauchamp L, Wooters J, Tilton JC, Long EO, Watzl C. Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244). Blood (2005) 105(12):4722-9. doi:10.1182/blood-2004-09-3796.
146. Dong Z, Davidson D, Pérez-Quintero LA, Kurosaki T, Swat W, Veillette A. The adaptor SAP controls NK cell activation by regulating the enzymes Vav-1 and SHIP-1 and by enhancing conjugates with target cells. Immunity (2012) 36(6):974-85. doi:10.1016/j.immuni.2012.03.023.
147. Sayos J, Wu C, Morra M, Wang N, Zhang X, Allen D, et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature (1998) 395:462-9. doi:10.1038/26683.
148. Latour S. Natural killer T cells and X-linked lymphoproliferative syndrome. Curr Opin Allergy Clin Immunol (2007) 7(6):510-4. doi:10.1097/ACI.0b013e3282f1bad6.
149. Ma CS, Nichols KE, Tangye SG. Regulation of cellular and humoral immune responses by the SLAM and SAP families of molecules. Annu Rev Immunol (2007) 25:337-79. doi:10.1146/annurev.immunol.25.022106.141651.
150. Snow AL, Marsh RA, Krummey SM, Roehrs P, Young LR, Zhang K, et al. Restimulation-induced apoptosis of T cells is impaired in patients with X-linked lymphoproliferative disease caused by SAP deficiency. J Clin Invest (2009) 119(10):2976-89. doi:10.1172/JCI39518.
151. Windhorst DB, Zelickson AS, Good RA. Chediak-Higashi syndrome: hereditary gigantism of cytoplasmic organelles. Science (1966) 151:81-3. doi:10.1126/science.151.3706.81.
152. Durchfort N, Verhoef S, Vaughn MB, Shrestha R, Adam D, Kaplan J, et al. The enlarged lysosomes in beige j cells result from decreased lysosome fission and not increased lysosome fusion. Traffic (2012) 13(1):108-19. doi:10.1111/j.1600-0854.2011.01300.x.
153. Huizing M, Helip-Wooley A, Westbroek W, Gunay-Aygun M, Gahl WA. Disorders of lysosome-related organelle biogenesis: clinical and molecular genetics. Annu Rev Genomics Hum Genet (2008) 9:359-86. doi:10.1146/annurev.genom.9.081307.164303.
154. Orange JS. Formation and function of the lytic NK-cell immunological synapse. Nat Rev Immunol (2008) 8(9):713-25. doi:10.1038/nri2381.
155. Theos AC, Tenza D, Martina JA, Hurbain I, Peden AA, Sviderskaya EV, et al. Functions of adaptor protein (AP)-3 and AP-1 in tyrosinase sorting from endosomes to melanosomes. Mol Biol Cell (2005) 16(11):5356-72. doi:10.1091/mbc.E05-07-0626.
156. Clark RH, Stinchcombe JC, Day A, Blott E, Booth S, Bossi G, et al. Adaptor protein 3-dependent microtubule-mediated movement of lytic granules to the immunological synapse. Nat Immunol (2003) 4:1111-20. doi:10.1038/ni1000.
157. Wenham M, Grieve S, Cummins M, Jones ML, Booth S, Kilner R, et al. Two patients with Hermansky Pudlak syndrome type 2 and novel mutations in AP3B1. Haematologica (2010) 95:333-7. doi:10.3324/haematol.2009.012286.
158. Stinchcombe J, Bossi G, Griffiths GM. Linking albinism and immunity: the secrets of secretory lysosomes. Science (2004) 305:55-9. doi:10.1126/science.1095291.
159. Shirakawa R, Higashi T, Tabuchi A, Yoshioka A, Nishioka H, Fukuda M, et al. Munc13-4 is a GTP-Rab27-binding protein regulating dense core granule secretion in platelets. J Biol Chem (2004) 279:10730-7. doi:10.1074/jbc.M309426200.
160. Neeft M, Wieffer M, de Jong AS, Negroiu G, Metz CH, van Loon A, et al. Munc13-4 is an effector of rab27a and controls secretion of lysosomes in hematopoietic cells. Mol Biol Cell (2005) 16(2):731-41. doi:10.1091/mbc.E04-10-0923.
161. Elstak ED, Neeft M, Nehme NT, Voortman J, Cheung M, Goodarzifard M, et al. The munc13-4-rab27 complex is specifically required for tethering secretory lysosomes at the plasma membrane. Blood (2011) 118(6):1570-8. doi:10.1182/blood-2011-02-339523.
162. Ménager MM, Ménasché G, Romao M, Knapnougel P, Ho CH, Garfa M, et al. Secretory cytotoxic granule maturation and exocytosis require the effector protein hMunc13-4. Nat Immunol (2007) 8:257-67. doi:10.1038/ni1431.
163. Kuroda TS, Fukuda M, Ariga H, Mikoshiba K. The Slp homology domain of synaptotagmin-like proteins 1-4 and Slac2 functions as a novel Rab27A binding domain. J Biol Chem (2002) 277:9212-8. doi:10.1074/jbc.M112414200.
164. Strom M, Hume AN, Tarafder AK, Barkagianni E, Seabra MC. A family of Rab27-binding proteins. Melanophilin links Rab27a and myosin Va function in melanosome transport. J Biol Chem (2002) 277:25423-30. doi:10.1074/jbc.M202574200.
165. Fukuda M, Kuroda TS, Mikoshiba K. Slac2-a/melanophilin, the missing link between Rab27 and myosin Va: implications of a tripartite protein complex for melanosome transport. J Biol Chem (2002) 277(14):12432-6. doi:10.1074/jbc.C200005200.
166. Jordens I, Westbroek W, Marsman M, Rocha N, Mommaas M, Huizing M, et al. Rab7 and Rab27a control two motor protein activities involved in melanosomal transport. Pigment Cell Res (2006) 19:412-23. doi:10.1111/j.1600-0749.2006.00329.x.
167. Holt O, Kanno E, Bossi G, Booth S, Daniele T, Santoro A, et al. Slp1 and Slp2-a localize to the plasma membrane of CTL and contribute to secretion from the immunological synapse. Traffic (2008) 9(4):446-57. doi:10.1111/j.1600-0854.2008.00714.x.
168. Ménasché G, Ménager MM, Lefebvre JM, Deutsch E, Athman R, Lambert N, et al. A newly identified isoform of Slp2a associates with Rab27a in cytotoxic T cells and participates to cytotoxic granule secretion. Blood (2008) 112:5052-62. doi:10.1182/blood-2008-02-141069.
169. Kurowska M, Goudin N, Nehme NT, Court M, Garin J, Fischer A, et al. Terminal transport of lytic granules to the immune synapse is mediated by the kinesin-1/Slp3/Rab27a complex. Blood (2012) 119:3879-89. doi:10.1182/blood-2011-09-382556.
170. Koch H, Hofmann K, Brose N. Definition of Munc13-homology-domains and characterization of a novel ubiquitously expressed Munc13 isoform. Biochem J (2000) 253:247-53. doi:10.1042/0264-6021:3490247.
171. Basu J, Shen N, Dulubova I, Lu J, Guan R, Guryev O, et al. A minimal domain responsible for Munc13 activity. Nat Struct Mol Biol (2005) 12(11):1017-8. doi:10.1038/nsmb1001.
172. Johnson JL, Hong H, Monfregola J, Kiosses WB, Catz SD. Munc13-4 restricts motility of Rab27a-expressing vesicles to facilitate lipopolysaccharide-induced priming of exocytosis in neutrophils. J Biol Chem (2011) 286:5647-56. doi:10.1074/jbc.M110.184762.
173. Pei J, Ma C, Rizo J, Grishin NV. Remote homology between Munc13 MUN domain and vesicle tethering complexes. J Mol Biol (2009) 391(3):509-17. doi:10.1016/j.jmb.2009.06.054.
174. Li W, Ma C, Guan R, Xu Y, Tomchick DR, Rizo J. The crystal structure of a Munc13 C-terminal module exhibits a remarkable similarity to vesicle tethering factors. Structure (2011) 19:1443-55. doi:10.1016/j.str.2011.07.012.
175. Boswell KL, James DJ, Esquibel JM, Bruinsma S, Shirakawa R, Horiuchi H, et al. Munc13-4 reconstitutes calcium-dependent SNARE-mediated membrane fusion. J Cell Biol (2012) 197(2):301-12. doi:10.1083/jcb.201109132.
176. Südhof TC, Rizo J. Synaptic vesicle exocytosis. Cold Spring Harb Perspect Biol (2011) 3(12):a005645.
177. Tang BL, Low DY, Hong W. Syntaxin 11: a member of the syntaxin family without a carboxyl terminal transmembrane domain. Biochem Biophys Res Commun (1998) 245(2):627-32. doi:10.1006/bbrc.1998.8490.
178. McNew JA, Weber T, Engelman DM, Söllner TH, Rothman JE. The length of the flexible SNAREpin juxtamembrane region is a critical determinant of SNARE-dependent fusion. Mol Cell (1999) 4:415-21. doi:10.1016/S1097-2765(00)80343-3.
179. Grote E, Baba M, Ohsumi Y, Novick PJ. Geranylgeranylated SNAREs are dominant inhibitors of membrane fusion. J Cell Biol (2000) 151:453-66. doi:10.1083/jcb.151.2.453.
180. Xu H, Zick M, Wickner WT, Jun Y. A lipid-anchored SNARE supports membrane fusion. Proc Natl Acad Sci U S A (2011) 108:17325-30. doi:10.1073/pnas.1113888108.
181. Dressel R, Elsner L, Novota P, Kanwar N, Fischer von Mollard G. The exocytosis of lytic granules is impaired in Vti1b- or Vamp8-deficient CTL leading to a reduced cytotoxic activity following antigen-specific activation. J Immunol (2010) 185:1005-14. doi:10.4049/jimmunol.1000770.
182. Loo LS, Hwang LA, Ong YM, Tay HS, Wang CC, Hong W. A role for endobrevin/VAMP8 in CTL lytic granule exocytosis. Eur J Immunol (2009) 39(12):3520-8. doi:10.1002/eji.200939378.
183. Hackmann Y, Graham SC, Ehl S, Höning S, Lehmberg K, Aricò M, et al. Syntaxin binding mechanism and disease-causing mutations in Munc18-2. Proc Natl Acad Sci U S A (2013) 110(47):E4482-91. doi:10.1073/pnas.1313474110.
184. Weninger K, Bowen ME, Choi UB, Chu S, Brunger AT. Accessory proteins stabilize the acceptor complex for synaptobrevin, the 1:1 syntaxin/SNAP-25 complex. Structure (2008) 16(2):308-20. doi:10.1016/j.str.2007.12.010.
185. Hu SH, Christie MP, Saez NJ, Latham CF, Jarrott R, Lua LH, et al. Possible roles for Munc18-1 domain 3a and Syntaxin1 N-peptide and C-terminal anchor in SNARE complex formation. Proc Natl Acad Sci U S A (2011) 108(3):1040-5. doi:10.1073/pnas.0914906108.
186. Rodkey T, Liu S, Barry M. Munc18a scaffolds SNARE assembly to promote membrane fusion. Mol Biol Cell (2008) 19(12):5422-34. doi:10.1091/mbc.E08-05-0538.